AcSé immunotherapy trials: anti-PD-1 therapy for adult patients with selected rare cancer types

Congress : ESMO

Authors : A. Marabelle, S. Chevret, F. Janot, B. Escudier, D. Pouessel, C. Tournigand, K. Hoang-Xuan, L. Mortier, B.J.-C. Rousseau, M.J. Schlumberger, I.L. Ray-Coquard, J.-Y. Blay, P. Niccoli, A. Jaccard, D. Couch, N. Hoog-Labouret, I. Pauporte, C. Massard

Experts group or program : Groupe immuno-oncologie (GIO)

Immune checkpoint blockade represents a major breakthrough in cancer therapy with recent approvals of PD-1 or PD-L1 antagonist therapy in France for a range of cancer indications. To generate high evidenced-based knowledge and to prevent off-label use, the French National Cancer Institute (INCa) launched the AcSé Immuno-therapy Program: two exploratory phase II trials, to allow for a nationwide safe and controlled access to nivolumab or pembrolizumab outside of their current marketing approvals for selected rare cancer indications where the literature suggests a potential benefit for patients, but where the difficulties of development render individual experimental studies unattractive to the pharmaceutical industry.

En savoir plus